Insights into the mechanisms involved in protective effects of VEGF-B in dopaminergic neurons

Beatrice Caballero, Scott J Sherman, Torsten Falk

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Vascular endothelial growth factor-B (VEGF-B), when initially discovered, was thought to be an angiogenic factor, due to its intimate sequence homology and receptor binding similarity to the prototype angiogenic factor, vascular endothelial growth factor-A (VEGF-A). Studies demonstrated that VEGF-B, unlike VEGF-A, did not play a significant role in angiogenesis or vascular permeability and has become an active area of interest because of its role as a survival factor in pathological processes in a multitude of systems, including the brain. By characterization of important downstream targets of VEGF-B that regulate different cellular processes in the nervous system and cardiovascular system, it may be possible to develop more effective clinical interventions in diseases such as Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and ischemic heart disease, which all share mitochondrial dysfunction as part of the disease. Here we summarize what is currently known about the mechanism of action of VEGF-B in pathological processes. We explore its potential as a homeostatic protective factor that improves mitochondrial function in the setting of cardiovascular and neurological disease, with a specific focus on dopaminergic neurons in Parkinson's disease.

Original languageEnglish (US)
Article number4263795
JournalParkinson's Disease
Volume2017
DOIs
StatePublished - 2017

Fingerprint

Vascular Endothelial Growth Factor B
Dopaminergic Neurons
Angiogenesis Inducing Agents
Pathologic Processes
Vascular Endothelial Growth Factor A
Parkinson Disease
Amyotrophic Lateral Sclerosis
Capillary Permeability
Sequence Homology
Cardiovascular System
Nervous System
Myocardial Ischemia
Cardiovascular Diseases
Brain

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Insights into the mechanisms involved in protective effects of VEGF-B in dopaminergic neurons. / Caballero, Beatrice; Sherman, Scott J; Falk, Torsten.

In: Parkinson's Disease, Vol. 2017, 4263795, 2017.

Research output: Contribution to journalReview article

@article{045b689ff9ad40e099c024b44236a200,
title = "Insights into the mechanisms involved in protective effects of VEGF-B in dopaminergic neurons",
abstract = "Vascular endothelial growth factor-B (VEGF-B), when initially discovered, was thought to be an angiogenic factor, due to its intimate sequence homology and receptor binding similarity to the prototype angiogenic factor, vascular endothelial growth factor-A (VEGF-A). Studies demonstrated that VEGF-B, unlike VEGF-A, did not play a significant role in angiogenesis or vascular permeability and has become an active area of interest because of its role as a survival factor in pathological processes in a multitude of systems, including the brain. By characterization of important downstream targets of VEGF-B that regulate different cellular processes in the nervous system and cardiovascular system, it may be possible to develop more effective clinical interventions in diseases such as Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and ischemic heart disease, which all share mitochondrial dysfunction as part of the disease. Here we summarize what is currently known about the mechanism of action of VEGF-B in pathological processes. We explore its potential as a homeostatic protective factor that improves mitochondrial function in the setting of cardiovascular and neurological disease, with a specific focus on dopaminergic neurons in Parkinson's disease.",
author = "Beatrice Caballero and Sherman, {Scott J} and Torsten Falk",
year = "2017",
doi = "10.1155/2017/4263795",
language = "English (US)",
volume = "2017",
journal = "Parkinson's Disease",
issn = "2090-8083",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Insights into the mechanisms involved in protective effects of VEGF-B in dopaminergic neurons

AU - Caballero, Beatrice

AU - Sherman, Scott J

AU - Falk, Torsten

PY - 2017

Y1 - 2017

N2 - Vascular endothelial growth factor-B (VEGF-B), when initially discovered, was thought to be an angiogenic factor, due to its intimate sequence homology and receptor binding similarity to the prototype angiogenic factor, vascular endothelial growth factor-A (VEGF-A). Studies demonstrated that VEGF-B, unlike VEGF-A, did not play a significant role in angiogenesis or vascular permeability and has become an active area of interest because of its role as a survival factor in pathological processes in a multitude of systems, including the brain. By characterization of important downstream targets of VEGF-B that regulate different cellular processes in the nervous system and cardiovascular system, it may be possible to develop more effective clinical interventions in diseases such as Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and ischemic heart disease, which all share mitochondrial dysfunction as part of the disease. Here we summarize what is currently known about the mechanism of action of VEGF-B in pathological processes. We explore its potential as a homeostatic protective factor that improves mitochondrial function in the setting of cardiovascular and neurological disease, with a specific focus on dopaminergic neurons in Parkinson's disease.

AB - Vascular endothelial growth factor-B (VEGF-B), when initially discovered, was thought to be an angiogenic factor, due to its intimate sequence homology and receptor binding similarity to the prototype angiogenic factor, vascular endothelial growth factor-A (VEGF-A). Studies demonstrated that VEGF-B, unlike VEGF-A, did not play a significant role in angiogenesis or vascular permeability and has become an active area of interest because of its role as a survival factor in pathological processes in a multitude of systems, including the brain. By characterization of important downstream targets of VEGF-B that regulate different cellular processes in the nervous system and cardiovascular system, it may be possible to develop more effective clinical interventions in diseases such as Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), and ischemic heart disease, which all share mitochondrial dysfunction as part of the disease. Here we summarize what is currently known about the mechanism of action of VEGF-B in pathological processes. We explore its potential as a homeostatic protective factor that improves mitochondrial function in the setting of cardiovascular and neurological disease, with a specific focus on dopaminergic neurons in Parkinson's disease.

UR - http://www.scopus.com/inward/record.url?scp=85018846589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018846589&partnerID=8YFLogxK

U2 - 10.1155/2017/4263795

DO - 10.1155/2017/4263795

M3 - Review article

AN - SCOPUS:85018846589

VL - 2017

JO - Parkinson's Disease

JF - Parkinson's Disease

SN - 2090-8083

M1 - 4263795

ER -